131 related articles for article (PubMed ID: 25363729)
21. Conformational stability of dimeric and monomeric forms of the C-terminal domain of human immunodeficiency virus-1 capsid protein.
Mateu MG
J Mol Biol; 2002 Apr; 318(2):519-31. PubMed ID: 12051856
[TBL] [Abstract][Full Text] [Related]
22. Accumulation of MxB/Mx2-resistant HIV-1 Capsid Variants During Expansion of the HIV-1 Epidemic in Human Populations.
Wei W; Guo H; Ma M; Markham R; Yu XF
EBioMedicine; 2016 Jun; 8():230-236. PubMed ID: 27428433
[TBL] [Abstract][Full Text] [Related]
23. Modular HIV-1 Capsid Assemblies Reveal Diverse Host-Capsid Recognition Mechanisms.
Summers BJ; Digianantonio KM; Smaga SS; Huang PT; Zhou K; Gerber EE; Wang W; Xiong Y
Cell Host Microbe; 2019 Aug; 26(2):203-216.e6. PubMed ID: 31415753
[TBL] [Abstract][Full Text] [Related]
24. MX2 Viral Substrate Breadth and Inhibitory Activity Are Regulated by Protein Phosphorylation.
Betancor G; Bangham M; Jeon JK; Shah K; Lynham S; Jimenez-Guardeño JM; Malim MH
mBio; 2022 Aug; 13(4):e0171422. PubMed ID: 35880880
[TBL] [Abstract][Full Text] [Related]
25. MX2 is an interferon-induced inhibitor of HIV-1 infection.
Kane M; Yadav SS; Bitzegeio J; Kutluay SB; Zang T; Wilson SJ; Schoggins JW; Rice CM; Yamashita M; Hatziioannou T; Bieniasz PD
Nature; 2013 Oct; 502(7472):563-6. PubMed ID: 24121441
[TBL] [Abstract][Full Text] [Related]
26. The pH dependence of HIV-1 capsid assembly and its interaction with cyclophilin A.
Bon Homme M; Wong S; Carter C; Scarlata S
Biophys Chem; 2003 Aug; 105(1):67-77. PubMed ID: 12932580
[TBL] [Abstract][Full Text] [Related]
27. MxB Is Not Responsible for the Blocking of HIV-1 Infection Observed in Alpha Interferon-Treated Cells.
Opp S; Vieira DA; Schulte B; Chanda SK; Diaz-Griffero F
J Virol; 2015 Dec; 90(6):3056-64. PubMed ID: 26719253
[TBL] [Abstract][Full Text] [Related]
28. Larger helical populations in peptides derived from the dimerization helix of the capsid protein of HIV-1 results in peptide binding toward regions other than the "hotspot" interface.
Doménech R; Bocanegra R; González-Muñiz R; Gómez J; Mateu MG; Neira JL
Biomacromolecules; 2011 Sep; 12(9):3252-64. PubMed ID: 21761887
[TBL] [Abstract][Full Text] [Related]
29. Dynamins are forever: MxB inhibits HIV-1.
Haller O
Cell Host Microbe; 2013 Oct; 14(4):371-3. PubMed ID: 24139395
[TBL] [Abstract][Full Text] [Related]
30. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
[TBL] [Abstract][Full Text] [Related]
31. Catalysis and binding of cyclophilin A with different HIV-1 capsid constructs.
Bosco DA; Kern D
Biochemistry; 2004 May; 43(20):6110-9. PubMed ID: 15147195
[TBL] [Abstract][Full Text] [Related]
32. Escherichia coli LysU is a potential surrogate for human lysyl tRNA synthetase in interactions with the C-terminal domain of HIV-1 capsid protein.
Boonyalai N; Pullen JR; Abdul Wahab MF; Wright M; Miller AD
Org Biomol Chem; 2013 Jan; 11(4):612-20. PubMed ID: 23208549
[TBL] [Abstract][Full Text] [Related]
33. Phage display of intact domains at high copy number: a system based on SOC, the small outer capsid protein of bacteriophage T4.
Ren ZJ; Lewis GK; Wingfield PT; Locke EG; Steven AC; Black LW
Protein Sci; 1996 Sep; 5(9):1833-43. PubMed ID: 8880907
[TBL] [Abstract][Full Text] [Related]
34. A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.
Lemke CT; Titolo S; Goudreau N; Faucher AM; Mason SW; Bonneau P
Acta Crystallogr D Biol Crystallogr; 2013 Jun; 69(Pt 6):1115-23. PubMed ID: 23695256
[TBL] [Abstract][Full Text] [Related]
35. Probing the potential glycoprotein binding site of sindbis virus capsid protein with dioxane and model building.
Lee S; Kuhn RJ; Rossmann MG
Proteins; 1998 Nov; 33(2):311-7. PubMed ID: 9779796
[TBL] [Abstract][Full Text] [Related]
36. [Effect of nucleocapsid on multimerization of gypsy structural protein Gag].
Semin BV; Leonova OG; Trendeleva TA; Zviagil'skaia RA; Il'in IuV; Popenko VI
Mol Biol (Mosk); 2012; 46(2):298-307. PubMed ID: 22670526
[TBL] [Abstract][Full Text] [Related]
37. Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution.
Worthylake DK; Wang H; Yoo S; Sundquist WI; Hill CP
Acta Crystallogr D Biol Crystallogr; 1999 Jan; 55(Pt 1):85-92. PubMed ID: 10089398
[TBL] [Abstract][Full Text] [Related]
38. MxB/Mx2: the latest piece in HIV's interferon puzzle.
Fackler OT; Keppler OT
EMBO Rep; 2013 Dec; 14(12):1028-9. PubMed ID: 24176933
[No Abstract] [Full Text] [Related]
39. A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2.
Goujon C; Greenbury RA; Papaioannou S; Doyle T; Malim MH
J Virol; 2015 Apr; 89(8):4676-80. PubMed ID: 25673704
[TBL] [Abstract][Full Text] [Related]
40. Interferon but not MxB inhibits foamy retroviruses.
Bähr A; Singer A; Hain A; Vasudevan AA; Schilling M; Reh J; Riess M; Panitz S; Serrano V; Schweizer M; König R; Chanda S; Häussinger D; Kochs G; Lindemann D; Münk C
Virology; 2016 Jan; 488():51-60. PubMed ID: 26609934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
